N/A
N=30
Sugars in Cigarettes
Tobacco Use
Bottom Line
View on ClinicalTrials.gov: NCT05308316 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Cigarettes with added sucrose (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Impact of Cigarette Sugar Content on Product Satisfaction. |
4.09; 3.89; 3.92; 4.39 | — |
| PRIMARY Impact of Sugar Content on Behavioral Outcomes Using the Multiple Choice Procedure Task. |
47.6; 27.20; 72.40; 113.8 | — |
| SECONDARY Other Subjective and Behavioral Measures: Effects/Liking |
47.85; 44.40; 47.33; 66.45 | — |
| SECONDARY Other Subjective and Behavioral Measures: Sensory Effect of Smoking |
3.33; 3.16; 3.42; 3.29 | — |
| SECONDARY To Evaluate the Impact of Sugar Content on Smoking Intensity |
— | — |
Summary
The aim of this study is to investigate the impact of sugar levels in cigarette tobacco on cigarette abuse liability and appeal. Participants will attend several clinic visits to smoke cigarettes with different levels of sugars and will complete multiple questionnaires to assess their experiences. Each of the sessions will be separated by at least 48 hours but not more than 5 days. The hypothesis is that the measures collected in this study will indicate lower abuse liability for cigarettes with lowest sugar content.
Eligibility Criteria
Inclusion Criteria
- Male or female age 21 years or older
- Smoking cigarettes that have been evaluated to have medium levels of sugar content
- No quit attempts in the past month nor intentions to quit smoking in the next month
- Participants are in good physical health (no unstable medical conditions) as determined by the licensed medical professional
- Participants are in stable, good mental health (e.g. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis) as determined by the licensed medical professional
- Stable vitals sign measurements (systolic BP ≤ 160 and >90 mmHg, diastolic BP ≤ 100 and >50 mmHg and heart rate ≤105 and > 45 bpm) as determined by the licensed medical professional
- Participants must be able to read for comprehension or completion of study documents (confirmed during informed consent process)
- Participants have provided written informed consent to participate in the study.
Exclusion Criteria
- Significant immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data as determined by the licensed medical professional
- Women who are pregnant or nursing or planning to become pregnant.
Data sourced from ClinicalTrials.gov (NCT05308316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.